Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

Aurora A Kinase Inhibitor

LY3295668

Gong X, et al¹; Goldenson B and Crispino JD²; Otto T and Sicinski P³; Rickman DS, et al⁴; Willems E, et al⁵

Target

Aurora kinases are believed to play a crucial role in cellular division by controlling chromosomal segregation. Defects in segregation can cause genetic instability, a condition highly associated with the formation of tumors. Aurora kinases—Aurora A, Aurora B, and Aurora C—are key mitotic regulators required for genome stability and are frequently overexpressed in cancerous tumors.

Molecule

LY3295668 has been shown in vitro and in vivo to be a highly selective Aurora A kinase inhibitor that targets cell-cycle dependency of sensitive tumors.¹

Clinical Development

LY3295668 is being investigated in a clinical trial in patients with neuroblastoma.

References

Gong X, et al. Cancer Discov. 2019;9(2):248-263.
Goldenson B, Crispino JD. Oncogene. 2015;34(5):537-545.
Otto T, Sicinski P. Nat Rev Cancer. 2017;17(2):93-115.
Rickman DS, et al. Cancer Discov. 2018;8(2):150-163.
Willems E, et al. Cell Div. 2018;13:7.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

View All Trials For This Molecule

DISCOVER OTHER MOLECULES

BTK Inhibitor

Learn More

PD-1 Inhibitor

Learn More

IDH1 Inhibitor

Learn More